Core fucosylated prostate-specific antigen (PSA) may be a diagnostic biomarker for differentiating prostate cancer from other prostate diseases, such as BPH 55, and both serum and urine tests for core fucosylated PSA are feasible options 56. Here, KLK3 is linked to benign prostatic hyperplasia.